Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1

2 hours ago 3

Soumya Eswaran

Wed, April 29, 2026 astatine 7:52 AM CDT 3 min read

Polen Capital, an concern absorption company, released its “Polen Focus Growth Strategy” first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. The archetypal 4th of 2026 was highly volatile for US equities, driven by AI disruption concerns and the US-Israel struggle successful Iran and the Middle East. In this backdrop, the Polen Focus Growth Strategy declined 17.16% successful the quarter, compared to a -9.78% instrumentality for the Russell 1000 Growth and -4.33% instrumentality for the S&P 500. The Strategy focuses connected mission-critical businesses with recurring gross and competitory advantages and capitalizes connected the volatility to summation investments successful bundle and semiconductor companies. The Strategy remains assured successful the semipermanent imaginable of the Portfolio, emphasizing businesses with beardown economical moats, robust equilibrium sheets, and multi-year net growth. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Polen Focus Growth Strategy highlighted stocks similar Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is simply a healthcare and aesculapian devices company. On April 28, 2026, Abbott Laboratories (NYSE:ABT) closed astatine $93.86 per share. One-month instrumentality of Abbott Laboratories (NYSE:ABT) was -8.32%, and its shares mislaid 28.21% implicit the past 52 weeks. Abbott Laboratories (NYSE:ABT) has a marketplace capitalization of $163.1 billion.

Polen Focus Growth Strategy stated the pursuing regarding Abbott Laboratories (NYSE:ABT) successful its Q1 2026 capitalist letter:

"At the aforesaid time, we exited our presumption in Abbott Laboratories (NYSE:ABT) during the quarter, pursuing a anterior simplification aft the institution announced its acquisition of Exact Sciences. The size and dilutive quality of the woody raised concerns astir superior allocation, which were reinforced by disappointing Q4 results that showed weaker than-expected integrated gross growth. With concern momentum deteriorating and accrued uncertainty tied to the acquisition, we judge stepping speech is the prudent people for now."

Daiwa Downgrades Abbott Laboratories (ABT), Sees Limited Upside

Abbott Laboratories (NYSE:ABT) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 71 hedge money portfolios held Abbott Laboratories (NYSE:ABT) astatine the extremity of the 4th quarter, up from 68 successful the erstwhile quarter. While we admit the imaginable of Abbott Laboratories (NYSE:ABT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article